Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016)
Gilead Sciences' (GILD) quarterly Current Deferred Revenue came in at $202.0 million in Q4 2016, down 54.09% YoY from $440.0 million in Q1 2016, and down 44.04% on a QoQ basis from $361.0 million in Q3 2016.
Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016) Analysis & Trends
Gilead Sciences (GILD) has 8 years of Current Deferred Revenue data on file, last reported at $202.0 million in Q4 2016.
- Quarterly Current Deferred Revenue fell 54.09% year-over-year to $202.0 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $202.0 million (down 54.09% YoY) and the FY2016 annual result came in at $202.0 million, down 54.09% from the prior year.
- Current Deferred Revenue retreated to $202.0 million in Q4 2016, from $361.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $529.0 million in Q1 2016 to a low of $93.7 million in Q2 2012.
- A 5-year average of $214.2 million and a median of $126.8 million in 2013 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2015 — Current Deferred Revenue surged 296.72% — and 2016, when it plunged 54.09%.
- Tracing GILD's Current Deferred Revenue over 5 years: stood at $103.2 million in 2012, then grew by 7.6% to $111.0 million in 2013, then increased by 20.72% to $134.0 million in 2014, then surged by 228.36% to $440.0 million in 2015, then sank by 54.09% to $202.0 million in 2016.
- The last three Current Deferred Revenue figures came in at $202.0 million (Q4 2016), $361.0 million (Q3 2016), and $345.0 million (Q2 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 202.00 Mn |
| Sep 30, 2016 | 361.00 Mn |
| Jun 30, 2016 | 345.00 Mn |
| Mar 31, 2016 | 529.00 Mn |
| Dec 31, 2015 | 440.00 Mn |
| Sep 30, 2015 | 356.00 Mn |
| Jun 30, 2015 | 501.00 Mn |
| Mar 31, 2015 | 191.00 Mn |
| Dec 31, 2014 | 134.00 Mn |
| Sep 30, 2014 | 116.88 Mn |
| Jun 30, 2014 | 126.28 Mn |
| Mar 31, 2014 | 111.79 Mn |
| Dec 31, 2013 | 111.00 Mn |
| Sep 30, 2013 | 127.28 Mn |
| Jun 30, 2013 | 112.12 Mn |
| Mar 31, 2013 | 124.37 Mn |
| Dec 31, 2012 | 103.16 Mn |
| Sep 30, 2012 | 99.05 Mn |
| Jun 30, 2012 | 93.66 Mn |
| Mar 31, 2012 | 100.19 Mn |